newsfilter
← Latest News
Business Wire·

Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD

  • Scholar Rock will present new clinical data & research updates at Cure SMA's Annual SMA Research & Clinical Care Meeting in Orlando, Florida (June 24-26, 2026) & the FSHD Society's 2026 International Research Congress on FSHD in Chicago, Illinois (June 25-26, 2026).
  • Presentations will cover the Phase 3 SAPPHIRE trial (NCT05156320) & Phase 2 FORGE study (NCT07435129) related to the company's neuromuscular portfolio.
  • At the Cure SMA meeting, Stacy Dixon will present a poster on Hammersmith Functional Motor Scale-Expanded impact on SMA patient independence (June 25, 4:00-6:00 PM ET), while Jing Marantz & Jena M. Krueger will deliver oral presentations on apitegromab efficacy baseline characteristics & Phase 3 post hoc analyses (June 26).
  • At the FSHD Society congress, John Staropoli will present a poster on the Phase 2 FORGE study trial design for adults with facioscapulohumeral muscular dystrophy (June 26, 12:35-2:00 PM CT).
  • Apitegromab is an investigational myostatin inhibitor that received FDA Fast Track, Orphan Drug, & Rare Pediatric Disease designations, as well as EMA PRIME & Orphan Medicinal Product designations for SMA treatment.
  • Apitegromab has not yet been approved by the FDA or any other regulatory agency.
  • Full presentation details will be available on Scholar Rock's website following each conference.